Skip to main content
. Author manuscript; available in PMC: 2016 Sep 2.
Published in final edited form as: Cancer Treat Res. 2015;166:193–226. doi: 10.1007/978-3-319-16555-4_9

Fig. 3.

Fig. 3

Effects of VEGF inhibitor (Sorafenib) and TGF-β inhibitor (LY364947) in the CT26 or BxPC3 model. a Vascular phenotypes revealed by immunofluorescence staining. Green, CD31 or platelet endothelial cell adhesion molecule (PECAM)-1; red, NG2. b Extravasation of 2 MDa dextran from vasculature. Dextran is shown in green and CD31/PECAM-1 in red. Scale bars = 100 μm. c and d are schemes that explain the different effects of VEGF inhibitor and TGF-β inhibitor on high or low-pericyte coverage tumors (Reproduced from Kano 2009, copyright of Elsevier)

HHS Vulnerability Disclosure